Roche to pay $42 million to Ascidian to make RNA exon editing drugs
Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.
HQ Team December 8, 2023: The USFDA has approved two treatments for sickle cell disease, one of them the first in the US.
HQ Team November 29, 2023: The University of Cambridge announced a partnership with AstraZeneca and the Medical Research Council to set up a functional genomics laboratory.
HQ Team November 1, 2023: AstraZeneca signed a $245 million deal with a French clinical-stage biotechnology firm, Cellectis, to speed up therapeutics in.
HQ Team August 14, 2023: Biomedical engineers at Johns Hopkins have developed a machine-learning model, which can turn on genes —an innovation which.
HQ Team July 10, 2023: US researchers have genetically edited mosquitoes to kill females of the species responsible for the spread of malaria..
HQ Team June 10, 2023:The Food and Drug Administration (FDA) has accepted an application for what could become the first-ever marketed medicine based.
The receptor of Oxytocin, a hormone considered essential to forming social bonds, may not play the role that scientists have assigned it for.